Fluidx Medical Begins Multinational Trial of GPX Embolic Device
December 5, 2024
November 27, 2024—Fluidx Medical Technology, Inc. announced that the first patient has been treated in the prospective, multinational, clinical trial of the company’s GPX embolic device. The device was successfully used in a portal vein embolization procedure in preparation for hepatic resection.
According to the company, the safety and effectiveness trial includes leading medical centers and investigators from the United States, Canada, and New Zealand. In May 2024, the company announced FDA approval of the investigational device exception for the GPX trial.
The initial procedure was discussed in the Fluidx press release by Stephen Chen, MD, who is the principal investigator at MD Anderson Cancer Center in Houston, Texas.
“We are pleased with the complete vessel filling we observed,” commented Dr. Chen. “GPX was easy to prepare, deliver, and use. We could see the material flow distally into the vessel segment, completely blocking blood flow to the target area. This was exactly what we were aiming for.”
Recent News
- Biolexis Therapeutics Advances Breakthrough GLP-1 and AMPK Programs into First-in-Human Clinical Trials
- Rebel Medicine Announces Series A Financing and Investigational New Drug (IND) Application Opening to Advance Non‑Opioid Pain Therapeutic into Clinical Development
- NUSANO STABLE ISOTOPE PROGRAM ENRICHES GADOLINIUM-160 TO 99.2% PURITY
- CancerVax Targets Liver Cancers to Further Showcase Flexibility of Its Universal Platform
- Seek Labs Unveils BioSeeker™
- Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)
